Multiple Sclerosis Trial, Recruiting (NCT04819737)

Multiple Sclerosis Trial, Recruiting NCT04819737 Sponsor: University Hospital, Basel, Switzerland Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT04819737 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with multiple sclerosis (MS) based on recognised international medical guidelines
You have not taken steroid medications for more than 4 weeks before joining the trial
You are already taking part in the Swiss MS Cohort (SMSC) study

Who may not be able to join:

You have a history of a serious neurological, internal (physical health), or psychiatric (mental health) condition that affects the spinal cord
You have certain metal objects inside your body, especially near the spine, such as implants or metal fragments (confirm with trial site)
You have a pacemaker (a device implanted to help control your heartbeat)
You experience severe anxiety in enclosed spaces (claustrophobia), which could make an MRI scan difficult
You are currently pregnant or breastfeeding
You have had a previous allergic or sensitivity reaction to a type of contrast dye called gadolinium, which is sometimes used during MRI scans

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Katrin Parmar, PD Dr. med., University Hospital Basel, Department of Neurology

Phone: +41 61 83 65 214

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04819737

Sponsor: University Hospital, Basel, Switzerland

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

Trial contact: +41 61 83 65 214

More information: https://clinicaltrials.gov/study/NCT04819737

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with multiple sclerosis (MS) based on recognised international medical guidelines
You have not taken steroid medications for more than 4 weeks before joining the trial
You are already taking part in the Swiss MS Cohort (SMSC) study

Who may not be able to join:

You have a history of a serious neurological, internal (physical health), or psychiatric (mental health) condition that affects the spinal cord
You have certain metal objects inside your body, especially near the spine, such as implants or metal fragments (confirm with trial site)
You have a pacemaker (a device implanted to help control your heartbeat)
You experience severe anxiety in enclosed spaces (claustrophobia), which could make an MRI scan difficult
You are currently pregnant or breastfeeding
You have had a previous allergic or sensitivity reaction to a type of contrast dye called gadolinium, which is sometimes used during MRI scans

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital, Basel, Switzerland

Registry

ClinicalTrials.gov

Start date

18 July 2022

Est. completion

1 December 2027

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Number of SC lesions; Inter-observer agreement on SC lesion count; Presence of ongoing inflammation (acute or chronic) in the SC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov